MG
CNTB

Michael Gelband’s Connect Biopharma Holdings CNTB Stock Holding History

Michael Gelband’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,400
Closed -$470K – 2213
2021
Q3 		$470K Buy
+19,400
New +$439K 0.01% 1434

Other funds holding CNTB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Michael Gelband's CNTB Position: Q4 2021 in Review

Michael Gelband sold out of Connect Biopharma Holdings (CNTB) in Q4 2021, closing a stake of 19,400 shares — an estimated $470K sold.

Michael Gelband first reported a position in CNTB in Q3 2021 and held it in 1 quarter. The position peaked at $470K in Q3 2021. 29 funds tracked by Wall St. Rank hold CNTB as of Q4 2021.

  • Michael Gelband reported no remaining Connect Biopharma Holdings position as of Q4 2021 after selling out during the quarter.
  • Michael Gelband sold 19,400 Connect Biopharma Holdings shares in Q4 2021, an estimated $470K.
  • Michael Gelband first reported a position in Connect Biopharma Holdings in Q3 2021 and held it in 1 quarter.
  • Michael Gelband's Connect Biopharma Holdings position peaked at $470K in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.